drugset / Trial / NCT05263895

Relative Bioavailability Study of 4 Different Formulations of PF-07321332 Relative to the Commercial Tablet Formulation

NCT05263895

Phase 1 Completed 12 enrolled Pfizer
RandomizedCrossoverOpen-labelBasic science

Summary

The purpose of this study is to estimate the relative bioavailability of PF-07321332 in different formulations in healthy adult participants.

Timeline

Start
2022-03-03
Primary completion
2022-05-16
Completion
2022-05-16

Drugs

EvaluationDrugModalityDoseRoute
Subject Nirmatrelvir Small molecule Oral
Subject Ritonavir Other / unclassified Oral

Indications

No indication recorded.